How Long Does It Take for Hydrocodone to Leave Your System?

Hydrocodone’s elimination half-life is roughly five to eight hours depending on the formulation, which means the drug itself clears your bloodstream within about one to two days after your last dose. But “leaving your system” and “no longer detectable on a drug test” are two different things. Metabolites of hydrocodone linger considerably longer than the parent drug, and detection windows vary dramatically by the type of test used.

What Happens to Hydrocodone After You Take It

Once you swallow an immediate-release hydrocodone tablet, blood levels climb quickly, peaking in roughly an hour. From there, the liver does most of the work. Two enzyme pathways handle the bulk of hydrocodone’s breakdown. One pathway, driven by an enzyme called CYP2D6, converts hydrocodone into hydromorphone, a more potent opioid that contributes to the drug’s pain-relieving effect. The other pathway, driven by CYP3A4, produces norhydrocodone, a largely inactive metabolite.¹ These two metabolites, along with smaller amounts of a third called dihydrocodeine, are what drug tests look for after the hydrocodone itself is gone.

The CYP3A4 pathway actually dominates in most people, so norhydrocodone ends up being the most abundant metabolite in urine. That matters for detection because norhydrocodone sticks around longer than the parent drug. In controlled studies, after a single 20 mg immediate-release dose, norhydrocodone remained detectable in urine for about 40 hours, compared to roughly 28 hours for hydrocodone itself.²

How Long Hydrocodone Shows Up in Blood

In blood and plasma, hydrocodone follows a fairly predictable arc. After an immediate-release dose, concentrations peak within about an hour, then decline steadily. One study found that parent drug concentrations in blood dropped below 300 ng/mL within 24 to 48 hours after a single dose.³ For a person taking a standard prescribed dose, blood levels typically fall below routine detection limits within a day or two. However, chronic users or people taking higher doses can have measurably higher baseline levels that take longer to clear completely.

The elimination half-life for immediate-release hydrocodone in healthy adults is about five hours, meaning every five hours the amount in your blood drops by roughly half.⁴ After five half-lives, which works out to about 25 hours, the drug has been reduced to a tiny fraction of its peak concentration. For most practical purposes, a single immediate-release dose is essentially gone from the blood within a day.

Urine Testing and Detection Times

Urine is by far the most common specimen for drug testing, and it offers a longer detection window than blood. The reason is straightforward: the kidneys concentrate the drug and its metabolites in urine, so even after blood levels have dropped to negligible amounts, urine can still test positive.

In a controlled clinical study with healthy volunteers who received a single 10 mg dose, hydrocodone appeared in urine within a few hours and peaked between three and a half to seven hours after the dose. Hydromorphone, the active metabolite, peaked later and at lower concentrations but persisted in urine for roughly as long as hydrocodone itself. Norhydrocodone showed up at higher concentrations than hydrocodone and lasted even longer.⁵ This makes norhydrocodone a particularly useful marker for confirming hydrocodone use.

A separate study using a 20 mg dose and more sensitive lab testing (with a cutoff of 50 ng/mL) reported detection times of about 28 hours for hydrocodone itself, about 40 hours for norhydrocodone, around 26 hours for hydromorphone, and roughly 16 hours for dihydrocodeine.² These numbers come from single-dose studies in healthy, drug-free adults. If you have been taking hydrocodone regularly, the drug and its metabolites accumulate, and the window stretches well beyond two days. Depending on dose, frequency, and individual metabolism, urine tests can stay positive for three to four days or sometimes longer after the last dose for chronic users.

Standard workplace immunoassay panels (the kind used in many employment screenings) detect opiates as a class, and their sensitivity and cutoff levels vary. Confirmatory testing with mass spectrometry can distinguish hydrocodone from other opioids and identify specific metabolites, which is why labs running legal or medical compliance tests use it. The practical upshot is that the detection window varies with the technology: a sensitive confirmatory assay catches lower concentrations, which extends the window.

Hair and Oral Fluid Testing

Hair testing sits at the opposite end of the timeline from blood. Hair grows slowly, and drugs are incorporated into the growing strand over weeks to months. In a study of volunteers, hydrocodone was detected in hair at concentrations ranging from 130 to nearly 16,000 pg/mg, and some specimens also contained hydromorphone.⁶ Hair testing generally provides a detection window of up to 90 days, though it is not useful for identifying recent use within the past week or so because the drug-containing portion of the hair has not yet grown above the scalp.

One nuance with hair testing for opioids is distinguishing actual use from environmental contamination. The metabolite ratios in hair can help: since hydromorphone and hydrocodone are formed during the body’s processing of certain opioids, their presence in specific ratios can indicate genuine ingestion rather than surface contamination.⁷

Oral fluid (saliva) testing has gained traction as a less invasive alternative to urine. Its detection window for hydrocodone is generally shorter than urine, typically about one to two days. One finding worth noting: in patients prescribed codeine, hydrocodone turned up as the most common metabolite in oral fluid samples, more often than morphine, which is the opposite of the pattern seen in urine.⁸ This is relevant because it means an oral fluid test can show hydrocodone even in someone who never took it directly, if they were prescribed codeine. That kind of cross-reactivity is a real-world headache for compliance monitoring programs.

Extended-Release Versus Immediate-Release Formulations

Hydrocodone comes in both immediate-release and extended-release forms, and the distinction meaningfully affects how long the drug lingers. An extended-release tablet is designed to release hydrocodone gradually, which means blood levels rise more slowly, peak later, and stay elevated longer.

In one study comparing the two, the immediate-release form peaked in under an hour with a half-life of about 5.1 hours, while the intact extended-release tablet peaked at around 7 hours and had a half-life of about 8 hours.⁴ That longer half-life means five half-lives works out to about 40 hours rather than 25, so the extended-release version takes roughly a day longer to fully clear from blood. Total systemic exposure (the overall amount of drug your body absorbs) remains similar between the two formulations at equivalent doses; it is the speed of absorption and the duration that differ.⁹

For urine testing, the extended-release version can shift the detection window modestly further out because peak urine concentrations arrive later and the tail of excretion stretches accordingly. If you are scheduled for a drug test and take extended-release hydrocodone, expect the detection window to be slightly longer than the numbers from immediate-release studies would suggest.

Genetic Differences in Metabolism

Not everyone processes hydrocodone at the same speed. The CYP2D6 enzyme that converts hydrocodone to hydromorphone is highly variable in the population. Some people are “extensive metabolizers” who process the drug efficiently, while “poor metabolizers” produce far less hydromorphone. In a study comparing these groups, the rate at which hydrocodone was converted to hydromorphone was about eight times faster in extensive metabolizers than in poor metabolizers.¹⁰

At the other end of the spectrum, “ultra-rapid metabolizers” carry extra copies of the CYP2D6 gene and convert hydrocodone to hydromorphone unusually fast, which can produce higher-than-expected levels of the active metabolite and increase the risk of side effects. These genetic differences do not drastically change how long hydrocodone is detectable in urine overall, because the various metabolites are still present either way. But the relative proportions of those metabolites shift, and a drug test that relies on the ratio of hydromorphone to hydrocodone may flag unusual results that reflect genetics rather than misuse.

In practical terms, your CYP2D6 status also affects how well hydrocodone works as a painkiller. One emergency department study found that patients who had taken other medications that inhibit CYP2D6 within 48 hours were only about a third as likely to get adequate pain relief from hydrocodone, compared to patients not taking those medications.¹¹ So the same enzyme that determines clearance speed also shapes whether the drug does its job in the first place.

Drug Interactions That Alter Clearance

Because hydrocodone depends heavily on CYP2D6 and CYP3A4 for breakdown, other drugs that compete for or inhibit these enzymes can change how fast (or slowly) hydrocodone leaves. Common CYP2D6 inhibitors include certain antidepressants like paroxetine and fluoxetine, as well as some antihistamines. When paroxetine (a potent CYP2D6 inhibitor) was given alongside extended-release hydrocodone in a controlled trial, the active metabolite hydromorphone dropped dramatically. However, the peak concentration, half-life, and overall exposure to hydrocodone itself did not change significantly.¹² In plain language, blocking the CYP2D6 pathway does not necessarily keep hydrocodone in your system longer, but it changes which metabolites appear in your blood and urine, and it blunts the drug’s pain-relieving effect.

The CYP3A4 pathway is a different story. Because CYP3A4 handles the dominant clearance route to norhydrocodone, strong inhibitors of CYP3A4 (like certain antifungals and some antibiotics) could theoretically slow hydrocodone clearance and raise blood levels. This is the basis for clinical concern about combining hydrocodone with CYP3A4 inhibitors. Interestingly, a large population-based study looking at hydrocodone combined with the CYP3A4-inhibiting calcium channel blockers diltiazem and verapamil found no statistically significant increase in opioid overdose risk compared to amlodipine, which does not inhibit CYP3A4.¹³ The interaction, while pharmacologically real, may be smaller in clinical practice than the theoretical pharmacology suggests. Still, prescribers adjust doses cautiously when strong CYP3A4 inhibitors are involved.

Kidney and Liver Problems Slow Things Down

Because hydrocodone is metabolized in the liver and its metabolites are excreted through the kidneys, impairment of either organ extends how long the drug stays in your body. In studies of an extended-release hydrocodone formulation, people with moderate kidney impairment had overall drug exposure about 70% higher than people with normal kidney function. Moderate liver impairment increased exposure by a similar margin.¹⁴

Higher exposure for the same dose means the drug is effectively staying in the bloodstream longer. For anyone with chronic kidney disease or liver conditions, this has two practical consequences: the drug’s effects (both therapeutic and side effects) last longer per dose, and the detection window on any drug test extends further. Prescribers typically start with lower doses and stretch out the intervals between doses for these patients.

Hydrocodone in Breast Milk

For nursing mothers prescribed hydrocodone after surgery or for pain management, a natural question is how long the drug takes to clear from breast milk. In the first published case reports on this, infants received an estimated 3 to 4 percent of the weight-adjusted maternal dose through breast milk. That is below the conventional threshold of concern. However, the absolute amount the infant gets depends on how much the mother is taking, and neonates and premature infants may be more vulnerable to opioid effects than older infants.¹⁵

Because hydrocodone’s half-life in blood is about five to eight hours, the drug’s concentration in breast milk follows a similar curve. Timing a nursing session several hours after a dose, when blood levels are falling, reduces the infant’s exposure, though it does not eliminate it. Moderate short-term use is generally considered acceptable, but the evidence base is thin, and there is no established safe upper limit for maternal dose during breastfeeding.

Why Forensic Toxicology Treats Hydrocodone Differently

In death investigations, toxicologists face a unique problem: drugs can redistribute within the body after death, moving from organs into the blood and potentially inflating postmortem blood concentrations. This “postmortem redistribution” can make it look like someone had more of a drug in their system than they actually did while alive. For some opioids, this is a major concern. Hydrocodone, however, appears relatively well behaved in this regard. One study found that the ratio of hydrocodone in central blood (near the heart, where redistribution is worst) to peripheral blood averaged only about 1.3, and the liver-to-blood ratio was around 3.0, which is considered low.¹⁶ Forensic pathologists consider hydrocodone to have minimal redistribution, which makes postmortem blood levels more reliable for interpretation than those of many other drugs.

This is one of those details that most living readers will never need, but it matters in legal and medical examiner contexts. When hydrocodone is involved in a death investigation, the postmortem blood concentration is relatively trustworthy as a reflection of the person’s actual drug level near the time of death, which is not something you can say for all opioids.